Rassnick, K. M., L. E. Williams, et al. (2008). "Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005)." J Am Vet Med Assoc 232(8): 1200-5.
Mast cell tumours (MCTs) are commonly diagnosed in cats, particularly in cutaneous locations. These tumours have a range of biological behavior from benign to malignant. Most cutaneous MCTs are readily treated with surgery or local radiation. Alternative treatments are needed for those cats where surgery or radiation is not an option, or where these modalities have failed to prevent recurrence. In this retrospective case series, the clinical efficacy and toxicity of lomustine was evaluated in 38 cats with confirmed mast cell tumors. Lomustine was administered at a dose at or equal to 50 mg/m(2). Of the 38 cats, most (68%) had cutaneous MCTs but tumors were also diagnosed in other locations, such as mesenteric lymph nodes. The overall response rate was 50%, with 7 cats having a complete response. The median duration of response was 168 days. The most commonly noted toxicoses were neutropenia and thrombocytopenia. The researchers conclude that lomustine should be considered for cats with MCTs where local treatment is not an option.
>> PubMed abstractRelated articles:
Turrel, J., J. Farrelly, et al. (2006). "Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002)." J Amer Vet Med Assoc 228(6): 898-901.
>> PubMed abstract